Latest quarter
Pfizer reported Q3 FY2026 revenue of $16.6 billion, above the consensus estimate of $16.1 billion but below the $16.7 billion reported a year earlier. Adjusted earnings per share were $0.87, compared with the consensus estimate of $0.72.
In its filing, Pfizer attributed the year-over-year revenue decline to COVID-19 products, the Prevnar vaccine family and other products, largely offset by growth in Eliquis, Padcev, the Vyndaqel family and other medicines. Excluding Comirnaty and Paxlovid, revenue grew 7% operationally. Pfizer attributed Eliquis growth primarily to higher U.S. net pricing and global demand, while it linked the Prevnar decline to lower vaccination rates and U.S. adult market-share erosion.
Pfizer reported diluted EPS of $0.57, down from $0.62 a year earlier. Gross margin rose to 75.7% from 74.9%, while operating margin declined to 22.1% from 23.1%. Free cash flow increased to $4.8 billion from $4.0 billion.
| Q3 FY2026 | Q3 FY2025 | Change | |
|---|---|---|---|
| Revenue | $16.6 billion | $16.7 billion | −0.43% |
| Diluted EPS | $0.57 | $0.62 | −8.79% |
| Gross margin | 75.7% | 74.9% | 0.8 percentage points |
| Operating margin | 22.1% | 23.1% | −1.0 percentage point |
| Free cash flow | $4.8 billion | $4.0 billion | 20.0% |
| Against the consensus | Reported | Consensus | Result |
|---|---|---|---|
| Adjusted EPS | $0.87 | $0.72 | Beat by 20.8% |
| Revenue | $16.6 billion | $16.1 billion | Beat by 2.80% |
Adjusted EPS is the figure the consensus estimates, not the GAAP EPS above.
What management said on the call
CEO Albert Bourla said launched and acquired products grew 32% operationally in the quarter. He said acquired products grew 37% operationally, while the legacy Seagen portfolio grew 39% year over year in the U.S., driven by Padcev.
CFO Cecile Guegan said launched and acquired products contributed $3.8 billion in quarterly revenue. She said non-COVID products grew 7% operationally, offset by lower COVID-19 product revenue. Guegan attributed the quarter’s adjusted gross margin of 77% primarily to product mix and cost management; she said the adjusted operating margin was 36%, tempered by the Innovent acquired research and development charge.
Asked about pricing, Guegan said quarterly performance was driven mostly by market performance and volume rather than changes in gross-to-net pricing. She noted an exception for Eliquis, where the effect of a January wholesale price decrease began in the third quarter. Bourla said Pfizer saw international opportunity for its oral migraine treatments while managing competition.
On investment, Bourla said Pfizer had made progress enrolling patients in its obesity studies. He said, “We are working toward the first in a series of potential approvals for berobenatide in 2028.” Executive Chris Boshoff said the Phase 2b amylin combination study was fully recruited and its efficacy readout was expected in the second half of 2027.
Asked about savings, Guegan said Pfizer expected its next phase of cost programs to mitigate margin erosion during the 2027–2029 loss-of-exclusivity transition. She said the company would provide 2027 guidance around the middle of December, with patent expirations, product launches, pricing and cost initiatives among the factors it would consider.
Guidance
Pfizer raised its FY2026 revenue guidance to $62.0 billion–$64.0 billion from $60.5 billion–$62.5 billion. It also raised and narrowed its adjusted diluted EPS outlook to $2.95–$3.05 from $2.80–$3.00. Guegan said the updated EPS range absorbed the $0.10 per-share impact of the Innovent transaction.
| Metric | For | Guide | Previous guide | Change |
|---|---|---|---|---|
| Operating expenses, Si and A Non Gaap | FY2026 | Pfizer expects FY2026 SI&A expenses to decline from the prior year. | — | — |
| Gross margin, non-GAAP | FY2026 | Pfizer expects FY2026 adjusted gross margin in the mid-70% range. | — | — |
| EPS, non-GAAP | FY2026 | $2.95–$3.05 | $2.80–$3.00 | Raised |
| Research and development, non-GAAP | FY2026 | $10.8 billion–$11.8 billion | — | New |
| Share repurchases | FY2026 | Pfizer does not anticipate share repurchases in FY2026. | Pfizer does not anticipate share repurchases in 2026. | — |
| Revenue | FY2026 | $62.0 billion–$64.0 billion | $60.5 billion–$62.5 billion | Raised |
| Tax rate, non-GAAP | FY2026 | 15.0% | — | New |
| Revenue, Covid-19 products | FY2026 | $4.0 billion | — | New |
| EPS, Adjusted Diluted | FY2026 | $0.10 | — | — |
| Revenue, Covid 19 | FY2026 | $4.0 billion | — | New |
| Units, Research and Development | FY2026 | 20 | — | — |
| EPS | FY2026 | $2.80–$3.00 | — | New |